Bioorganic and Medicinal Chemistry Letters p. 3594 - 3597 (2012)
Update date:2022-07-31
Topics:
Asakawa, Chiharu
Ogawa, Masanao
Fujinaga, Masayuki
Kumata, Katsushi
Xie, Lin
Yamasaki, Tomoteru
Yui, Joji
Fukumura, Toshimitsu
Zhang, Ming-Rong
N-(2-{3-[3,5-Bis(trifluoromethyl)]phenylureido}ethyl)glycyrrhetinamide (2), an ureido-substituted derivative of glycyrrhetinic acid (1), has been reported to display potent inhibitory activity for proteasome and kinase, which are overexpressed in tumors. In this study, we labeled this unsymmetrical urea 2 using [11C]phosgene ([11C]COCl2) as a labeling agent with the expectation that [11C]2 could become a positron emission tomography ligand for the imaging of proteasome and kinase in tumors. The strategy for the radiosynthesis of [11C]2 was to react hydrochloride of 3,5-bis(trifluoromethyl)aniline (4·HCl) with [ 11C]COCl2 to possibly give isocyanate [11C]6, followed by the reaction of [11C]6 with N-(2-aminoethyl) glycyrrhetinamide (3).
View MoreShangHai Ruiyi Medical Technology Co.,Ltd.
Contact:+86-21-54718086
Address:No951 Jianchuan RD,Minhang District
Zhengzhou Institute of Chiral Pharmer Research Co., Ltd.
Contact:86-371-55219111
Address:15 Floor, 2 Building, Central China Technovalley, Zhongyuan West Road
NANCHANG QINZHI SCI&TEC.CO.,LTD(expird)
Contact:+86-13687004106
Address:Hero South Road,Hero Zone,Nanchang,Jiangxi,China
Jinan Hongfangde Pharmatech Co.LTD
Contact:0531-88870908
Address:F Bldg,750#,Shunhua Rd,New&High-tech Zone,Jinan,Shandong,China 250101
SHANGHAI ARCADIA BIOTECHNOLOGY LTD.
Contact:+86-21-61353236
Address:SUITE 901, BUILDING WENSLI, 1378 LU JIA BANG RD, SHANGAHI 200011, P.R.CHINA
Doi:10.1016/j.bmcl.2012.04.037
(2012)Doi:10.1039/c2cc33701k
(2012)Doi:10.1002/aoc.2858
(2012)Doi:10.1016/S0960-894X(00)00423-6
(2000)Doi:10.1016/j.jphotochem.2012.01.008
(2012)Doi:10.1055/s-0033-1340847
(2014)